[Chemoembolization combined with hepatic arterial induction of endogenous TNF and anticancer agents for hepatocellular carcinoma--a case report].
Antitumor effect of TNF has been demonstrated to be increased with some kinds of anticancer agents. We reported antitumor effect of hepatic endogenous TNF induced with gamma-IFN and OK-432 for hepatocellular carcinoma (HCC). To increase antitumor effect of transcatheter arterial embolization (TAE), hepatic arterial chemoembolization was performed with a mixture of gamma-IFN, OK-432 and gelatin sponge following a mixture of Doxorubicin and iodized oil (LPO) on the first time. Serum alpha-fetoprotein decreased from 18,903 ng/ml to 470 ng/ml but elevated three months after these procedures. Following the above procedure, hepatic arterial embolization with a mixture of gelatin sponge and Actinomycin D as an inhibitor of RNA was given the second time. Serum alpha-fetoprotein decreased under 5 ng/ml and computed tomography revealed decreased tumor size and low density area following this second procedure. Hepatic arterial chemoembolization with a mixture of hepatic induction of endogenous TNF and anticancer agents may well be beneficial for survival of patient with HCC.
Takekoshi
H
H
Dept. of Internal Medicine, Tokyoto Saiseikai Central Hospital.
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001688:Biological Products / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D003609:Dactinomycin / Q000008:administration & dosage; D003692:Delayed-Action Preparations; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004621:Embolization, Therapeutic; D005781:Gelatin Sponge, Absorbable / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007371:Interferon-gamma / Q000008:administration & dosage*; D007459:Iodized Oil / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D010844:Picibanil / Q000008:administration & dosage*; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology*
D001688:Biological Products; D003692:Delayed-Action Preparations; D014409:Tumor Necrosis Factor-alpha; D003609:Dactinomycin; D010844:Picibanil; D007459:Iodized Oil; D004317:Doxorubicin; D007371:Interferon-gamma